<table>
<tr><td rowspan="6">Oropharynx /Unknown primary
ECRIC 28%

Stage I-II
MALTHUS
10%</td><td rowspan="5">Fit for curative treatment
99%
MALTHUS</td><td rowspan="3">Primary Radiotherapy
85-95%
MALTHUS</td><td>Conventional Fractionation*
10% NNUH est</td><td colspan="3">66 Gy/33 f T1 20% NNUH est

70 Gy/35 f T2 80% NNUH est</td></tr>
<tr><td rowspan="2">Altered fractionation</td><td rowspan="2">Accelerated fractionation</td><td>Normal//hyperfractionated</td><td>RTOG 72Gy 42f CB
Danish 6f per week</td></tr>
<tr><td>Hypofractionated RT</td><td>55 Gy 20 f , 65 Gy 30 f</td></tr>
<tr><td rowspan="2">Primary Surgery incl. pt choice 5-15%
MALTHUS</td><td>PORT
30% est MALTHUS</td><td colspan="3">Conventional fractionation* 60 Gy /30f', 66 Gy /33f
Hypofractionation 50 Gy 20f, 55 Gy 20f</td></tr>
<tr><td colspan="4">No PORT 70% est MALTHUS</td></tr>
<tr><td rowspan="2">Not fit for curative therapy1%
MALTHUS</td><td>PRT 25% est NNUH</td><td colspan="4">8 Gy/1f , 20 Gy/5f , 27 Gy/6f est 30 Gy /10f</td></tr>
<tr><td>No Rt</td><td colspan="4">75% est NNUH</td></tr>
<tr><td rowspan="6">Stage III-IV
MALTHUS
90%</td><td rowspan="6">Stage III-IVB
MALTHUS
95%</td><td rowspan="6">Fit for curative therapy 90-95% est MALTHUS</td><td rowspan="4">Disease suitable for curative therapy 95% est MALTHUS</td><td rowspan="2">Primary RT +/- CT
Very MDT dependant
70-80% est MALTHUS</td><td>Conventional fractionation*</td><td>68 Gy 34f
70 Gy 35f</td></tr>
<tr><td>Altered fractionation</td><td>Accelerated Normal/hyperfractionation
DAHANCA 68Gy 34f
Hypofractionation 65Gy/30 f, 55 Gy 20 f [</td></tr>
<tr><td rowspan="2">Primary Surgery including debulking nodes 25%
MALTHUS</td><td>Not accelerated
Hyperfractionated 81.6/68f</td></tr>
<tr><td>PORT
Should be 100%
MALTHUS est 90%</td><td>Conventional fractionation* 60 Gy 30 f
66 Gy 33f microscopic
70 Gy 35 f macroscopic residual
Hypofractionation 50 Gy 20f, 55 Gy 20f</td></tr>
<tr><td colspan="2">No PORT 10 % est MALTHUS</td></tr>
<tr><td rowspan="2">Disease unsuitable for curative therapy < 5%</td><td>Palliative RT</td><td colspan="2">60% est MALTHUS NNUH est 80%</td></tr>
<tr><td>No RT</td><td colspan="2">40% est MALTHUS NNUH est 20%</td></tr>
</table>

		Unfit for curative therapy 5-10 % MALTHUS	Palliative Radiotherapy 60%	8 Gy/1# , 20 Gy/5# , 27 Gy/6# , 30 Gy /10#
			No Radiotherapy 40%	
	Stage IVC MALTHUS 2 %	Symptomatic 70%	Fit for palliative Radiotherapy 90%, 8 Gy/1# , 20 Gy/5# , 27-36 Gy/6# , 30 Gy /10#	
			Unfit for palliative radiotherapy 10%	
		Asymptomatic 30%		

Oral cavity and lip 28% DAHNO Stage I-IVB 98%	Suitable for curative surgery and RT MALTHUS 90%	Surgery preference [Clinician or patient preference] 50% est MALTHUS [except T4 invading bone]	PORT 40% MALTHUS estimate	Conventional fractionation*66-70 Gy in 33-35 # If adverse factors-micro to macro residual disease, Hypofractionation 50 Gy 20f, 55 Gy 20f
			No PORT 60% MALTHUS estimate	
		Fit for and chose radiotherapy 50% est MALTHUS	Conventional fractionation*66-70 Gy in 33-35 # If adverse factors-micro to macro residual disease, Normo/hyperfractionated DAHANCA 68/34 f, 81.2 Gy/68 f Hypofractionation 50 Gy 20f, 55 Gy 20f, 90% MALTHUS	
			Palliative RT 10% MALTHUS	
	Unsuitable for curative surgery MALTHUS 5 %	Fit for radiotherapy 95% MALTHUS	Curative RT Conventional fractionation*66-70 Gy in 33-35 #, If adverse factors-micro to macro residual disease, Normo/hyperfractionated DAHANCA 68/34 f, 81.2 Gy/68 f Hypofractionation 50 Gy 20f, 55 Gy 20f, 85% NNUH	
			Palliative RT 15% NNUH	
	Unsuitable RT or Surgery 5%			
IVC 2%	Symptomatic 70% NNUH est	Fit for palliative Rt 90% NNUH est		
		Unfit for palliative Rt 10% NNUH est		
	Asymptomatic 30% NNUH est			

Nasopharyngeal Cancer 2% DAHNO and ECRIC	Stage I-IVB 98% MALTHUS	Fit for radiotherapy 99% MALTHUS	Suitable for curative Radiotherapy 95% MALTHUS	Conventional Fractionation*	66 Gy in 33 f 70 Gy in 35 f
			Unsuitable for curative Radiotherapy 5% MALTHUS	Palliative Radiotherapy 95% [PRT] MALTHUS	8 Gy 1 f, 20 Gy 5 f, 27-36 Gy 6 f, 30 Gy 10 f
				No Radiotherapy 5% MALTHUS	
		Not fit for radiotherapy 1% MALTHUS			
	Stage IVC 2 % MALTHUS	Symptomatic 100% MALTHUS	Fit for palliative radiotherapy 90% MALTHUS	Local PRT 60% MALTHUS	8 Gy 1 f, 20 Gy 5 f, 27-36 Gy 6 f, 30 Gy 10 f
				Distant PRT MALTHUS	8 Gy 1 f, 20 Gy 5 f
			Not fit for palliative RT 10% MALTHUS		
		Asymptomatic 0% MALTHUS			

<table>
<tr><td rowspan="5">Nasal cavity & Paranasal sinuses

Stage I-II
MALTHUS est 20%</td><td rowspan="3">Fit for surgery
95% NNUH est</td><td colspan="3">PORT[13] 60 Gy/30 f, 66 Gy/33 f 80% NNUH est</td></tr>
<tr><td colspan="3">No RT NNUH est 20%</td></tr>
<tr><td rowspan="3">Not fit for surgery 5%
NNUH est</td><td rowspan="2">Fit for RT[14]
80% NNUH est</td><td>Conventional fractionation * 70 Gy/35 f
Hypofractionation 55 Gy/20 f [70% est NNUH]</td></tr>
<tr><td>Palliative Radiotherapy PRT [30% est NNUH]
8 Gy 1 f, 20 Gy 5 f, 27-36 Gy 6 f, 30 Gy 10 f</td></tr>
<tr><td colspan="2">Not fit for RT 20% NNUH est</td></tr>
<tr><td rowspan="3">Stage III-IVB
78 % est MALTHUS

T3-T4a
80% NNUH est</td><td>Fit for surgery and
PORT NNUH est 95%</td><td colspan="3">Conventional fractionation* 60 Gy/30f, 66 Gy/33 f, 70 Gy/35 f
Hypofractionation 55 Gy/20 f</td></tr>
<tr><td rowspan="2">Not fit for surgery *
NNUH est 5 %</td><td rowspan="2">Fit for RT NNUH est
80%</td><td>Conventional fractionation* 70 Gy/35 f
Hypofractionation 55 Gy/20 f , 70 % est NNUH</td></tr>
<tr><td>30 % PRT est NNUH</td></tr>
<tr><td colspan="3">Not fit for RT NNUH est 20%</td></tr>
<tr><td rowspan="5">T4b 20% NNUH est</td><td rowspan="3">Suitable for curative surgery NNUH est 20%</td><td>Fit for surgery and
PORT NNUH est 95%</td><td colspan="2">Conventional fractionation*
60 Gy/30f, 66 Gy/33 f,70 Gy/35 f
Hypofractionation 55 Gy/20 f</td></tr>
<tr><td rowspan="2">Unfit for surgery and
PORT NNUH est 5%</td><td>Fit for Radiotherapy
NNUH est 80%</td><td>Conventional fractionation*70 Gy/35 f
Hypofractionation 55 Gy/20 f NNUH est 90%</td></tr>
<tr><td>PRT [10% est NNUH]</td></tr>
<tr><td colspan="2">Unfit for Radiotherapy NNUH est 20%</td></tr>
<tr><td rowspan="3">Unsuitable for curative surgery NNUH est 80%</td><td rowspan="3">Fit for Radiotherapy
NNUH est 90%</td><td>Curative intent NNUH
est 30%</td><td>Conventional fractionation* 70 Gy/35 f
Hypofractionation 55 Gy/20 f</td></tr>
<tr><td>Palliative radiotherapy
[70% est NNUH]</td><td></td></tr>
<tr><td colspan="3">Not fit for Radiotherapy NNUH est 10%</td></tr>
<tr><td rowspan="4">IVC 2% est NNUH</td><td rowspan="2">Symptomatic 50% est
NNUH</td><td rowspan="2">Fit for palliative RT 90%
NNUH est</td><td>Local 60% NNUH est</td></tr>
<tr><td>Distant 40% NNUH est</td></tr>
<tr><td colspan="2">Not fit for radiotherapy 10% NNUH est</td></tr>
<tr><td>Asymptomatic 50% est
NNUH</td><td colspan="2"></td></tr>
</table>

<table>
<tr><td rowspan="8">Glottic Larynx
19% DAHNO 6</td><td colspan="2" rowspan="4">70% larynx
Stage I-II or Tis
MALTHUS</td><td rowspan="3">Fit for curative therapy
95%
MALTHUS</td><td rowspan="2">70-90%
Primary RT
MALTHUS</td><td colspan="3">Conventional[3]
Fractionation*
66 Gy/33 f T1
70/35 Gy/35 f T2</td></tr>
<tr><td colspan="3">16-20#
Hypofractionation[9]</td></tr>
<tr><td rowspan="2">10-30%
Primary surgery
MALTHUS</td><td colspan="3">10-15% MALTHUS
PORT[6]
60 Gy/30 f,
66 Gy/33 f
70/35 Gy/35 f</td></tr>
<tr><td colspan="3">No PORT
90% MALTHUS</td></tr>
<tr><td rowspan="2">Not fit for curative therapy
5%
MALTHUS</td><td>Fit for PRT
20 % NNUH</td><td colspan="3">RT 8 Gy 1 f, 20 Gy 5 f, 27-36 Gy 6 f, 30 Gy 10 f</td></tr>
<tr><td>Not fit for PRT
80% NNUH</td><td colspan="3">No RT</td></tr>
<tr><td rowspan="4">30%
Stage III-IV</td><td rowspan="4">95%
Stage III-IVB</td><td rowspan="4">Disease suitable for laryngeal preservation
~</td><td rowspan="3">Curative RT [3-6]
90%
MALTHUS</td><td colspan="3">Conventional fractionation 70 Gy/35 f*</td></tr>
<tr><td rowspan="3">Altered fractionation</td><td rowspan="2">Accelerated</td><td>Normo / hyperfractionated[4]
DAHANCA 68
Gy/34 f</td></tr>
<tr><td>Hypofractionated
65 Gy/30 f,
55Gy/20 f</td></tr>
<tr><td>Non accelerated</td><td>Hyperfractionated
81.2 Gy/68 f</td></tr>
<tr><td>10%
MALTHUS</td><td>PRT[8]
See above</td><td colspan="2"></td></tr>
</table>

<table>
<tr><td rowspan="12"></td><td rowspan="12"></td><td rowspan="9"></td><td></td><td rowspan="2">Not fit for curative RT</td><td></td><td colspan="2" rowspan="2"></td></tr>
<tr><td>No RT</td></tr>
<tr><td rowspan="7">Disease not suitable for laryngeal preservation ~50% MALTHUS</td><td rowspan="4">90% MALTHUS Suitable for surgery</td><td rowspan="2">Fit for surgery</td><td>80% PORT[7]</td><td rowspan="2">As above</td></tr>
<tr><td>20% No PORT</td></tr>
<tr><td rowspan="3">Not fit for surgery</td><td rowspan="2">RT[3-6]</td><td>“Curative” RT Conventional fractionation 70 Gy/35 f*</td></tr>
<tr><td>PRT as above</td></tr>
<tr><td colspan="2">No RT</td></tr>
<tr><td rowspan="3">10% MALTHUS Not suitable for surgery</td><td rowspan="2">RT probably</td><td colspan="2">Curative RT[3-6] Conventional fractionation 70 Gy/35 f*</td></tr>
<tr><td colspan="2">PRT[8]</td></tr>
<tr><td colspan="3">No RT</td></tr>
<tr><td rowspan="3">1% Stage IVC NNUH est</td><td rowspan="2">Symptomatic 80% NNUH est</td><td>Fit for RT 90% NNUH est</td><td rowspan="2">PRT</td><td>Local PRT[8] 60% NNUH est 8 Gy 1 f, 20 Gy 5 f, 27-36 Gy 6 f, 30 Gy 10 f</td></tr>
<tr><td>Not fit for RT 10% NNUH est</td><td>Distant PRT[8] 40% NNUH Est 8 Gy 1 f, 20 Gy 5 f</td></tr>
<tr><td>Asymptomatic 20% NNUH est</td><td colspan="3">No RT</td></tr>
</table>

Metastatic neck nodes skin primary 5%	Suitable and fit for surgery 95% est MALTHUS	PORT est 90% MALTHUS	Conventional fractionation[13] 70 Gy/35 * Hypofractionated 55Gy/20 f, 50 Gy/20 f[15]
		No RT est 10% MALTHUS	
	Not fit for surgery 5% est MALTHUS	Palliative radiotherapy est 90% NNUH	
		No RT. est 10% est 10% NNUH	

<table>
<tr><td rowspan="4">Hypopharynx and supra glottic

Stage I-II
10% NNUH est</td><td rowspan="3">Fit for curative therapy 99% MALTHUS</td><td rowspan="2">Primary RT
80% NNUH est</td><td colspan="2">Conventional fractionation* 66 Gy /33 f, 70 Gy/ 35f
Altered fractionation normo /hyperfr. 72Gy/42 f,
Hypofr. 55 Gy/20 f, 65 Gy/30f</td></tr>
<tr><td rowspan="2">Primary surgery
20% NNUH est</td><td colspan="2">PORT
Conventional fractionation* 60 Gy/30 f, 66Gy/33 f, 70 Gy/35f Hypofr. 55 Gy/20 f, 65 Gy/30f 30% MALTHUS</td></tr>
<tr><td colspan="2">No RT 70% MALTHUS</td></tr>
<tr><td rowspan="2">Unfit for curative therapy 1% MALTHUS</td><td colspan="3">Palliative RT 25% NNUH est</td></tr>
<tr><td colspan="3">No RT 75% NNUH est</td></tr>
<tr><td rowspan="4">Stage III-IVB
85 % est NNUH</td><td rowspan="4">Fit for curative therapy
80% NNUH est</td><td rowspan="3">Disease suitable for curative therapy
80% NNUH</td><td>Primary RT +/- chemotherapy
30% NNUH est</td><td>Conventional fractionation*
66Gy/33 f,70 Gy/35f
Altered fractionation norno/hyperfr. 72Gy/42 f,
Hypofr. 55 Gy/20 f, 65 Gy/30f</td></tr>
<tr><td rowspan="2">Primary surgery 70% NNUH est</td><td>PORT
Conventional fractionation*
60 Gy/30 f, 66Gy/33 f, 70 Gy/35f
Hypofr. 55 Gy/20 f, 65 Gy/30f
90% NNUH est</td></tr>
<tr><td>No PORT 10% NNUH est</td></tr>
<tr><td>Disease not suitable for curative therapy
20% NNUH</td><td colspan="2">Palliative radiotherapy
30% NNUH est</td></tr>
<tr><td rowspan="3">IVC
5% est NNUH</td><td rowspan="3">Symptomatic
50% est NNUH</td><td rowspan="2">Fit for palliative RT 90% est NNUH</td><td colspan="2">Local PRT 60% est NNUH</td></tr>
<tr><td colspan="2">Distant 40% est NNUH</td></tr>
<tr><td colspan="3">Unfit for palliative RT
10% est NNUH</td></tr>
<tr><td colspan="4">Asymptomatic
50% est NNUH</td></tr>
</table>

Salivary Gland Tumours 6%	Fit for surgery 95% NNUH est	PORT 80% NNUH est	Conventional fractionation* 70 Gy/35 f, 66 Gy/33 f, 60 Gy/30 f Hypofractionation 55 Gy/20 f, 50 Gy/20 f
		No PORT 20% NNUH est	
	Unfit for surgery 5% NNUH est	Palliative Radiotherapy 80% NNUH est	
		No RT 20% NNUH est	

References

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. E J Cancer 2010;46:765-81.

2. Curado MP, Edwards B, Shin HR et al. (eds), Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160. Lyon: IARC 2007.

3. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press 2005.

4. Edge B, Byrd D, Compton C, et al AJCC Cancer Staging Manual 7th ed. New York: Springer; 2010.

5. Barret A, Dobbs J, Morris S, Roques T. Head and neck tumors. Practical Radiotherapy Planning. 4th Ed. Hodder Arnold; 2009:88-195.

6. Halperin E, Perez C, Brady L. Head and Neck tumors. Perez and Brady's Principles and Practice of Radiation Oncology, 5th Ed. Philadelphia: Lippincott Williams & Wilkins; 2008:778-1075.

7. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.

8. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005;27:843-50.

9. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.

10. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.

11. Mendenhall WM, Hinerman RW, Amdur RJ et al. Postoperative radiotherapy for squamous cell carcinoma of the head and neck. Clin Med Res. 2006 Sep;4(3):200-8.

12. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 2003;362:933-40.

13. Saunders MI, Rojas AM, Parmar MK et al; CHART Trial Collaborators. Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):3-8.

14. Bourhis J, Lapeyre M, Tortochaux J et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol. 2006 Jun 20;24(18):2873-8.

15. Bourhis J, Calais G, Lapeyre M et al; French Head and Neck Cancer Group (GORTEC). Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC). Semin Oncol. 2004 Dec;31(6):822-6.

16. Fu KK, Pajak TF, Trotti A. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16.

17. Bourhis J, Overgaard J, Audry H, et al. Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-54.

18. Porceddu SV, Rosser B, Burmeister BH, et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment – "Hypo Trial". Radiother Oncol 2007;85:456-62.

19. Wei WI, Kwong DL. Current management strategy of nasopharyngeal carcinoma. Clin Exp Otorhinolaryngol. 2010 Mar;3(1):1-12. Epub 2010 Mar 30.

20. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr;16(4):1310-7.

21. Baujat B, Audry H, Bourhis J, et al; MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):47-56.

22. Setton J, Caria N, Romanyshyn J et al. Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. Int J Radiat Oncol Biol Phys. 2010 Dec 16. [Epub ahead of print]

23. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127-36.

24. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996 Jul 3;88(13):890-9.

25. Wang CC. Radiotherapeutic management and results of T1N0, T2N0 carcinoma of the oral tongue: evaluation of boost techniques. Int J Radiat Oncol Biol Phys 1989 Aug;17(2):287-91

26. Sher DJ, Thotakura V, Balboni TA et al. Treatment of Oral Cavity Squamous Cell Carcinoma with Adjuvant or Definitive Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2011 Apr 29. [Epub ahead of print]

27. Studer G, Zwahlen R, Graetz K et al. IMRT in oral cavity cancer. Radiation Oncology 2007, 2:16

28. Terhaard CHJ, Lubsen H, Rasch CRN, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005;61:103-11.

29. Armstrong JG, Harrison LB, Spiro RH, et al. Malignant tumors of major salivary gland origin: A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 1990;116:290-3.

30. Dirix P, Vanstraelen B, Jorissen M, et al. Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:998-1004.

31. Daly ME, Chen AM, Bucci MK, et al. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys 2007;67:151-7.

32. Hoppe BS, Nelson CJ, Gomez DR, et al. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys 2008;72:763-9.

Guidelines

1. Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v184-6.

2. National Institute for Health and Clinical Excellence (NICE). Service guidance on improving outcomes in head and neck cancers [Internet]. London: National Institute for Health and Clinical Excellence (NICE); 2004. Available from: http://www.nice.org.uk/

3. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of head and neck cancer. A national clinical guideline [Internet]. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2006 Oct. SIGN publication No.: 90. Available from: http://www.sign.ac.uk/

4. Cancer Care Ontario (CCO). The Management of Head and Neck Cancer in Ontario: Organizational and Clinical Practice Guideline Recommendations [Internet]. Ontario (Canada): Cancer Care Ontario (CCO); 2009 Dec. CCO Evidence-Based Series #5-3: Section 1. Available from: http://www.cancercare.on.ca/

5. Cancer Care Ontario (CCO). The Role of IMRT in Head & Neck Cancer:
Guideline Recommendations [Internet]. Ontario (Canada): Cancer Care Ontario (CCO); 2011 Jan. CCO Evidence-Based Series #21-3-3 Section 1. Available from: http://www.cancercare.on.ca/

6. Cancer Care Ontario (CCO). Optimum Radiation Fractionation for T1 N0 Glottic (Vocal Cord) Carcinoma [Internet]. Ontario (Canada): Cancer Care Ontario (CCO); 2011 Jan. CCO Evidence Summary Report # 5-4. Available from: http://www.cancercare.on.ca/

7. The Royal College of Radiologists (RCR). Publications and guidance. Radiotherapy Dose-Fractionation. Head and neck cancers [Internet]. London: The Royal College of Radiologists (RCR); 2006 July. Available from: http://www.rcr.ac.uk/

8. Chan AT, Grégoire V. Lefebvre J-L et al; EHNS-ESMO-ESTRO Guidelines Working Group. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5:v187 (2010).

9. Pfister DG, Laurie SA, Weinstein GS et al. American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006 Aug 1;24(22):3693-704. Epub 2006 Jul 10.

10. Kaanders JH, Hordijk GJ; Dutch Cooperative Head and Neck Oncology Group. Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care and rehabilitation. Radiother Oncol. 2002 Jun;63(3):299-307.